Madrigal Pharmaceuticals Reports 2018 Fourth Quarter and Full Year Financial Results and Highlights

NEXT STORY
Eidos Therapeutics Initiates ATTRibute-CM, a Phase 3 Study of AG10 in ATTR-CM with Registrational 12-month Endpoint
PREV STORY
CytoDyn to Present New Data from Study of Investigational HIV Therapy Leronlimab (PRO 140), a Long-Acting, Single-Agent Maintenance Therapy at CROI 2019
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Shineco, Inc. Enters into a Letter of Intent to Acquire Controlling Interest in Changzhou Biowin Pharmaceutical Co., Ltd

author_avatar
NASDAQ Market News

Merus gibt Finanzergebnisse für das erste Quartal bekannt und legt ein Update zur Geschäftsentwicklung vor

author_avatar
NASDAQ Market News

Almac Group Opens Companion Diagnostic Laboratory in Durham N.C.

CRAIGAVON, Northern Ireland, March 08, 2016 (GLOBE NEWSWIRE) -- Almac Group – a contract ...

author_avatar
NASDAQ Market News